Effects of an Anal Insert Device in Fecal Incontinence (NCT03898778) | Clinical Trial Compass
CompletedNot Applicable
Effects of an Anal Insert Device in Fecal Incontinence
United States124 participantsStarted 2019-05-16
Plain-language summary
The purpose of this research is to test the effects of an inserted anal device on fecal incontinence (accidental bowel leakage) in patients who have persistent symptoms despite other conservative therapy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
* Able to provide signed (written) informed consent
* Diagnosis of fecal incontinence, with duration of symptoms six months or longer with a history of at least one fecal incontinence (FI) episode per week or at least four episodes per month
* Subject comprehends study meaning and is capable of carrying out study duties
* Patient is fluent in English as study questionnaires have been validated using English
* If female and of childbearing potential, patient has had a negative urine pregnancy test within 21 days of the first day of the baseline visit
* If applicable, patient agrees to use acceptable birth control (surgical sterilization, abstinence, approved hormonal contraceptives such as birth control pills, barrier methods such as condom or diaphragm used with a spermicide, or an intrauterine device (IUD)). If not applicable, the reason why shall be documented on the screening log.
* Subject is at least 18 years of age at time of consent
* Patients has failed conservative medical therapy (i.e., the use of bulking agents, anti-diarrheal agents (e.g., loperamide) and biofeedback therapy as appropriate) for Fecal Incontinence
Exclusion Criteria
* Unable or unwilling to provide informed consent or to comply with study procedures
* History of anorectal pathology in the past 6 months (perianal abscess or fistula, fecal impaction, or clinically significant rectocele).
* History of inflammatory bowel disease with active proctosigmoiditis
* History of rectal su…
What they're measuring
1
Primary Effectiveness Endpoint
Timeframe: Baseline (Weeks 1-4) through Treatment period (Weeks 9-12)